Adam Crystal

TNGX President (R&D) sells 27,000 shares for $798,908.18 under scheduled 10b5-1 plan; retains 115,743 shares plus 314,040 options.

Adam Crystal, President of R&D, executed two separate sales totaling 27,000 shares for $798,908.18 on 2026-07-01, reducing his non-derivative holding by 18.9% but remaining with 115,743 shares and retaining 314,040 stock options. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-10-27, meaning it was scheduled rather than discretionary. Tango Therapeutics remains deeply unprofitable (net income of $-45,514,000 for its most recent full fiscal year) while posting 48.3% annual revenue growth, a profile consistent with early-stage biotech. Crystal's prior trades at this ticker show mixed 30-day outcomes (ranging from +29.1% to -17.8%) and no measurable 90-day outcomes, limiting inference about his historical accuracy specific to TNGX. The scheduled nature of this disposition precludes timing-based judgment.

Adam Crystal (TNGX President, R&D) sold 27,000 shares in 2 transactions on 2026-06-01 for $617.6K via scheduled 10b5-1 plan.

Adam Crystal executed 2 separate sales totaling 27,000 shares for $617,571.27 at blended average price $22.87, reducing his non-derivative holdings by 18.9% to 115,743 shares post-transaction. The sales were executed via a pre-arranged 10b5-1 trading plan adopted on 2025-10-27, making this a scheduled transaction rather than a discretionary timing decision. Crystal retains 341,040 shares in stock option holdings (Table II derivative securities). The stock is currently trading at $21.47, down 5.5% over 30 days and down 24.4% from its 52-week high of $28.41, despite a +27.6% gain over 90 days. The company reported zero latest-quarter revenue and annual net income of -$45.5M, though it showed 48.3% annual revenue growth. His prior sales at TNGX have shown mixed outcomes: two recent May sales posted +3.7% and -0.1% 30-day returns, while an April 15 sale yielded -17.8% 30-day performance. The scheduled nature of this transaction removes discretionary timing as an interpretive lens; investors should focus on the composition of remaining holdings (both non-derivative and derivative) relative to the company's unprofitable operating status.

Tango President of R&D buys 27K shares while net-selling 27K in same day; aggressive stock recovery amid steep losses

Crystal Adam, President of R&D at Tango Therapeutics, executed a complex same-day transaction on May 1st: purchasing 27,000 shares while simultaneously selling a nearly equivalent volume. The buy component adds meaningful capital commitment at a time when the stock is trading well below its recent highs after a significant pullback. Critically, this move occurs while the company is unprofitable with substantial annual losses, making Adam's decision to accumulate shares despite weak fundamentals noteworthy. However, the offsetting sell of roughly the same share count within hours raises questions about whether this represents genuine conviction or opportunistic tax-loss harvesting or option exercise mechanics. For a R&D leader at a therapeutics company, the timing and structure of this trade deserve closer scrutiny to understand whether Adam sees value ahead or is simply rebalancing positions.

R&D President Crystal Adam sold 38,460 shares at $25.00 for $961,500, reducing stake by 25.5% to 112,622 shares held.

Crystal Adam, President of R&D at Tango Therapeutics, sold 38,460 shares at $25.00 on 2026-04-15, representing a 25.5% reduction in her stated holdings from 151,082 shares to 112,622 shares. The transaction occurs near the 52-week high of $25.33, with the stock up 34.0% over 30 days and 92.5% over 90 days. Adam's cross-ticker track record shows 2 prior open-market sells with an average 30-day return of +50.8%, while her TNGX-specific history includes a sell 14 days prior (2026-04-01) and another on 2026-02-25 that returned +50.8% over 30 days. The company posted positive net income of $15,884,000 in the latest quarter against revenue of $53,811,000, though it remained unprofitable on a full-year basis, and has grown annual revenue 48.3% year-over-year. The timing and magnitude of this sale—reducing exposure by over one-quarter near recent highs amid strong price momentum—warrants investor attention given the tight succession of three sales within six weeks and the prior transaction's positive near-term outcome.

President, R&D Crystal Adam sells 27,000 TNGX shares at $21.20; stock at 52-week high, +88.1% in 30 days

Crystal Adam (President, R&D) sold 27,000 shares at $21.20 on 2026-04-01, reducing holdings from 139.6K to 112.6K shares. The transaction occurred at the 52-week high of $21.63 (current price), following an 88.1% rally over 30 days and 142.2% gain over 90 days. While Adam's cross-ticker track record shows 1 prior sell with a 30-day return of +50.8%, this represents only a single data point across all tickers. At TNGX specifically, Adam has only 1 prior measurable trade (a sell on 2026-02-25 with 30-day +50.8% outcome), leaving insufficient history to establish a pattern of timing accuracy at this security. The company's fundamentals reflect recent profitability ($15.9M net income in the latest quarter) and strong quarterly revenue growth of +48.3% year-over-year, though it was unprofitable over the full prior fiscal year, suggesting recent inflection.

TNGX: President of R&D Crystal Adam sold 54,345 shares at $12.77 (2/25/2026) via pre-arranged 10b5-1 plan

Crystal Adam, serving as President of R&D at Tango Therapeutics, sold 54,345 shares at $12.77 on 2026-02-25 under a pre-arranged 10b5-1 trading plan adopted on 2025-10-27. This execution represents a scheduled, non-discretionary reduction of 29.0% against pre-transaction holdings, bringing her position from 187,218 shares to 132,873 shares. As a 10b5-1 plan, the transaction timing and parameters were fixed in advance and do not reflect current market views or recent developments. The sale occurred at modest volume and maintains a substantial residual stake in the company.